Epstein–Barr virus vaccine

Epstein–Barr virus vaccine is a term for a vaccine against the Epstein–Barr virus. The virus establishes persistent/latent infection and causes infectious mononucleosis. Vaccines are not yet available,[1] but it is in clinical trials.[2][3][4] The viral protein Gp350/220 is the primary target[5] and MVA-EL has been also proposed as a target.[6]

One challenge is that the Epstein–Barr virus expresses very different proteins during its lytic and its latent phases.[7] To address this, vaccine candidates have been designed to include proteins from both phases.[7]

References

  1. ↑ Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; et al. (December 2007). "Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults". J. Infect. Dis. 196 (12): 1749–53. doi:10.1086/523813. PMID 18190254.
  2. ↑ Crawford, D.H.; Macsween, K.F.; Higgins, C.D.; et al. (August 2006). "A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis". Clin. Infect. Dis. 43 (3): 276–82. doi:10.1086/505400. PMID 16804839.
  3. ↑ Elliott, S.L.; Suhrbier, A.; Miles, J.J.; et al. (February 2008). "Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis". J. Virol. 82 (3): 1448–57. doi:10.1128/JVI.01409-07. PMC 2224445Freely accessible. PMID 18032491.
  4. ↑ Moutschen, M.; Léonard, P.; Sokal, E.M.; et al. (June 2007). "Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults". Vaccine. 25 (24): 4697–705. doi:10.1016/j.vaccine.2007.04.008. PMID 17485150.
  5. ↑ "WHO | Viral Cancers". Retrieved 2009-01-15.
  6. ↑ Taylor, G.S.; Haigh, T.A.; Gudgeon, N.H.; et al. (January 2004). "Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma". J. Virol. 78 (2): 768–78. doi:10.1128/JVI.78.2.768-778.2004. PMC 368843Freely accessible. PMID 14694109.
  7. 1 2 Lockey, T.D.; Zhan, X.; Surman, S.; Sample, C.E.; Hurwitz, J.L. (2008). "Epstein-Barr virus vaccine development: a lytic and latent protein cocktail". Front. Biosci. 13 (13): 5916–27. doi:10.2741/3126. PMID 18508632.


This article is issued from Wikipedia - version of the 10/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.